Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Haleon

Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch

Here is what they are not talking about on CNBC right now.

Benzinga

Trump tariffs: Which UK sectors will be hit hardest?

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

Evening Standard

Pfizer offloads final shares in Sensodyne maker Haleon

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Investors Business Daily

Revenues fall at Sensodyne maker Haleon after weaker painkiller sales

Shares were lower in early trading on Thursday as a result.

The Independent UK

FTSE 100 Live 31 October: Budget fears hit housebuilding and retail stocks, Shell beats forecasts

Housebuilding and retail stocks have fallen sharply amid the fallout from yesterday’s tax-raising Budget.

Evening Standard

You Can Stop Looking, Here's the Perfect Stock for the Current Market

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading…

Barchart

Read news from The Economist, FT, and more,
with one subscription

FTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale

GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results.

Evening Standard

FTSE 100 Live 1 May: US Fed notes ‘lack of further progress’ on inflation as it holds interest rates

Forecast-beating results by Shell and Standard Chartered today boosted their shares during another robust session for the FTSE 100 index.

Evening Standard

Advert taken off air after facing backlash from Grenfell Tower victims for editing out building

An advert has been taken off air after facing a backlash from Grenfell Tower victims for editing the building out of a scene.

Evening Standard

‘Really upsetting’: Grenfell Tower edited out of TV advert

Exclusive: Man whose uncle died in 2017 disaster describes ad for pain relief gel Voltarol as ‘insulting’

The Guardian - UK

Robitussin Cough Syrups Recalled Due To Microbial Contamination

The distributors have been notified and provided with instructions for the return of all recalled products.

Medical Daily

Robitussin cough syrups recalled in the US due to microbial contamination

UK-based company Haleon recalls eight batches of cough syrup over risk to immunocompromised individuals

The Guardian - US

What is the PanaNatra line of painkillers and can herbal products effectively relieve pain?

In an era where chronic pain affects millions worldwide, the search for effective and safe pain relief has never been greater.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

An Under the Radar Healthcare Stock to Add to Your Portfolio

The era of the giant pharmaceutical conglomerate is coming to a close, but consumer-focused Haleon stock looks set to deliver healthy returns through long-term economic cycles.

The Guardian - UK

Panadol maker plans sweeping job cuts a year after being spun off from GSK

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

The Hindu

Busy day in London for KTR, team

The Guardian - UK

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Moonpig flotation price, like so many, was always pie-in-the-sky thinking

You’d think fund mangers would have deployed degree of scepticism after years of overvalued businesses

The Guardian - UK

‘I no longer need a magnifying glass’: a visually impaired travel writer tests an app that ‘reads’ for him

Rob Crossan, a freelance journalist and radio presenter, has a visual impairment, and finds shopping for healthcare products less than straightforward. Will an app by Microsoft make it easier?

The Guardian - UK

How a blind engineer developed an AI app to help people with sight loss

The designer of a groundbreaking text-reading app, that started life as a Microsoft side-project, explains how it’s now a lifeline for blind people and those with literacy issues

The Guardian - UK

‘PE was seen as a health and safety risk’: why sport must be accessible for people with sight loss

For blind and partially sighted people to experience the life-changing benefits of sport, more needs to be done to remove obstacles to participation

The Guardian - UK

‘The app gave me the information’: how technology enables visually impaired people to ‘see’

An app that can read out labels on healthcare products is at the cutting edge of a technology revolution that is helping improve accessibility for people with sight loss

The Guardian - UK

I tested an AI app for visually impaired people – and this is what I found

The Microsoft Seeing AI app aims to assist people who are visually impaired with buying health products. Elin Williams, 24, author of the disability and lifestyle blog My Blurred World, gives it a go – and reveals her verdict

The Guardian - UK

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.